What Royalty Pharma plc does.

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, which includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Biogen’s Tysabri and Spinraza, Roche’s Evrysdi, Astellas and Pfizer’s Xtandi, Johnson & Johnson’s Tremfya, AbbVie and Johnson & Johnson’s Imbruvica, Servier’s Voranigo, Gilead’s Trodelvy, Amgen’s Imdelltra and Alnylam’s Amvuttra, among others, and 20 development-stage product candidates.

We strive to be the premier capital allocator in life sciences with consistent, compounding growth. Our highly selective investment approach focuses on identifying and tracking important new therapies, which allows us to act efficiently when opportunities arise. Supported by an experienced investment team, a rigorous due diligence process and a focus on high-quality therapies addressing significant unmet patient needs, we pursue royalty opportunities that best meet our investment criteria.

Revenue and profit, by fiscal year.

More on RPRX.

• Royalty Pharma plc summary
• Royalty Pharma plc financial statements
• Royalty Pharma plc key metrics
• Royalty Pharma plc health scores and style box
• Royalty Pharma plc earnings
• Royalty Pharma plc dividends
• Royalty Pharma plc valuation
• Royalty Pharma plc ownership and insiders
• Royalty Pharma plc peers

Figures from Royalty Pharma plc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.